Enveric Biosciences (NASDAQ:ENVB) Issues Earnings Results

Enveric Biosciences (NASDAQ:ENVB) issued its earnings results on Friday. The company reported ($0.76) EPS for the quarter, FiscalAI reports.

Enveric Biosciences Price Performance

NASDAQ:ENVB opened at $1.53 on Friday. The firm has a 50-day moving average of $1.44 and a 200-day moving average of $2.12. The company has a market cap of $5.65 million, a PE ratio of -0.07 and a beta of 1.13. Enveric Biosciences has a one year low of $1.25 and a one year high of $17.64.

Analyst Upgrades and Downgrades

ENVB has been the subject of a number of research reports. Wall Street Zen cut Enveric Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Enveric Biosciences currently has an average rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.